AiMOGA Robotics, a Chery brand, unveiled Mobo, its first consumer humanoid robot designed for home companionship, at the 2026 Chery International User Summit. Mobo uses advanced AI to understand complex commands, navigate home environments, and remember family preferences while ensuring privacy. The launch marks AiMOGA's expansion from commercial to consumer markets, leveraging Chery's automotive R&D and supply chain expertise. Global pre-orders for Mobo are now open, signaling a new phase in smart home robotics with practical, scalable solutions for daily life.
AiMOGA Robotics' new humanoid robot Mobo launches globally with pre-orders open. For readers following Technology-sector US stocks, here is Pluang's market snapshot as of Oct 17, 2026 23:11 WIB: out of 150 stocks, 11 rose and 139 fell. Notable movers include AEHR at USD 60.60 with a -12.44% change and 80% buy orders, NBIS at USD 165.47 down -12.18% with 59% buy orders, and APLD at USD 18.05 down -11.48% with 82% buy orders.
Chery Auto will showcase its purpose-built Level 4 (L4) Robotaxi at the 2026 Chery International User Summit and sign a strategic cooperation agreement with UAE-based K2. The Robotaxi offers a fully driverless passenger experience from booking to rid...
AiMOGA Robotics, a Chery brand, unveiled Mobo, its first consumer-grade humanoid robot designed for home companionship, at the 2026 Chery International User Summit. Powered by AiMOGA's proprietary AI system MoAgent, Mobo can interpret complex command...
AiMOGA Robotics, a Chery brand, will debut Mobo, its first consumer-grade humanoid robot designed as a home companion, at the 2026 Chery International User Summit in Wuhu, China. Mobo features advanced AI for understanding complex commands, spatial a...
AiMOGA Robotics, a brand under Chery, introduced Mobo, its first consumer-grade humanoid robot designed as a family companion, at the 2026 Chery International User Summit. Mobo operates with AiMOGA's proprietary MoAgent AI, enabling it to understand ...
Ascendis Pharma announced that the European Medicines Agency's CHMP has issued a positive opinion recommending approval of TransCon CNP (navepegritide), a once-weekly treatment for achondroplasia in children aged two and older with open growth plates...
